INS and type 1 diabetes mellitus: In the EDITION JP 1 and EDITION JP 2 trials, respectively, Gla-300 has been demonstrated to reduce the frequency of confirmed or severe nocturnal hypoglycemia over Gla-100 in T1DM and T2DM patients with prior insulin experience over a 6-month study period [16, 18].